Telmisartan and Losartan in Hypertensive IGT

• Register: ClinicalTrials.gov
• Last refreshed on: 19 February 2015
• Main ID: NCT00407862
• Date of registration: 04/12/2006
• Prospective Registration: No
• Primary sponsor: Medical University of Graz
• Public title: Telmisartan and Losartan in Hypertensive IGT
• Scientific title: Telmisartan vs. Losartan in Hypertensive Patients With Impaired Glucose Tolerance: A Comparison of Their Antihypertensive, Metabolic, and Vascular Effects
• Date of first enrolment: January 2005
• Target sample size: 24
• Recruitment status: Completed
• URL: http://clinicaltrials.gov/show/NCT00407862
• Study type: Interventional
• Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment
• Phase: Phase 4

Countries of recruitment

Austria

Contacts

• Name: Thomas C. Wascher, MD
• Affiliation: Medical University of Graz

Key inclusion & exclusion criteria

Inclusion Criteria:

- IGT according the criteria of the WHO

- standardised office blood pressure > 140/90 mmHG or treated hypertension

- 40 - 75 years of age

- signed informed consent

Exclusion Criteria:

- known hypersensitivity towards telmisartan or losartan

- concommitant treatment with ACE-inhibitors

- BMI > 35 kg/m2

- inability to perform self-control of blood pressure

- acute coronary syndrome or cerebrovascular event within the last 3 months

- Revascularisation within the last 3 months

- heart failure > NYHA 2



Age minimum: 40 Years
Age maximum: 75 Years
Gender: Both

Health Condition(s) or Problem(s) studied

Hypertension

Impaired Glucose Tolerance

Intervention(s)

Drug: Losartan 50 mg

Drug: Telmisartan 80 mg

Primary Outcome(s)

Blood pressure surge in the morning

ISI

FMD

HOMA index

Secondary ID(s)

TCW-02-04

Source(s) of Monetary Support

Please refer to primary and secondary sponsors